CompletedPhase 1NCT01929226
Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers
Studying Inhalational anthrax
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Elusys Therapeutics
- Principal Investigator
- Alex King, MD, mdCovance
- Intervention
- ETI-204(biological)
- Enrollment
- 280 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2013
Study locations (1)
- Covance Clinical Research Inc., Dallas, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01929226 on ClinicalTrials.gov